These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21992405)

  • 21. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
    van Mourik MS; Cameron A; Ewen M; Laing RO
    BMC Cardiovasc Disord; 2010 Jun; 10():25. PubMed ID: 20534118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries?
    Cherla A; Howard N; Mossialos E
    Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value-based tiered pricing for universal health coverage: an idea worth revisiting.
    Chalkidou K; Claxton K; Silverman R; Yadav P
    Gates Open Res; 2020; 4():16. PubMed ID: 32185365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Availability and affordability of essential medicines for children in the Western part of Ethiopia: implication for access.
    Sado E; Sufa A
    BMC Pediatr; 2016 Mar; 16():40. PubMed ID: 26979737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
    Shaw B; Mestre-Ferrandiz J
    Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing medicine price transparency through price information mechanisms.
    Hinsch M; Kaddar M; Schmitt S
    Global Health; 2014 May; 10():34. PubMed ID: 24885767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries.
    Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Torres Rueda S; Kiefer S; O'Connell K; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Poyer S; Chavasse D
    Health Policy Plan; 2016 Mar; 31(2):148-60. PubMed ID: 25944705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.
    Moye-Holz D; Vogler S
    Appl Health Econ Health Policy; 2022 Jan; 20(1):67-77. PubMed ID: 34228312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Access to cardiovascular medicines in low- and middle-income countries: a mini review.
    Harrison MA; Marfo AFA; Annan A; Ankrah DNA
    Glob Health Res Policy; 2023 May; 8(1):17. PubMed ID: 37221559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug makers to cut prices for developing countries.
    AIDS Alert; 1998 Aug; 13(8 Suppl):1-2. PubMed ID: 11365655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
    Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M
    Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability, pricing and affordability of selected medicines for noncommunicable diseases.
    Heidari E; Varmaghani M; Abdollahiasl A
    East Mediterr Health J; 2019 Oct; 25(7):473-480. PubMed ID: 31612979
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.